Nosocomial Proton Pump Inhibitor Administration and the Impact on Hospital-Acquired Clostridium Difficile Infection Development: Evidence and Possible Mechanism.
Am J Med. 2017 Nov 06;:
Authors: Wombwell E, Chittum ME, Leeser KR
Abstract
The incidence of Clostridium difficile infection continues to rise globally. Particularly concerning are hospital-acquired cases which attribute significant morbidity, mortality, and expenditures to the healthcare system. Proton pump inhibitors which are widely prescribed and generally considered to have minimal adverse effects, have recently come under scrutiny for positive associations with C. difficile infection development. This article will specifically review the current state of evidence demonstrating a positive association between nosocomial proton pump inhibitor administration and the incidence of hospital-acquired C. difficile infection. In addition, the article delivers state-of-the-art knowledge relative to mechanisms by which proton pump inhibitor exposure may propagate the manifestation of C. difficile infection.
PMID: 29122635 [PubMed - as supplied by publisher]